Global Community

A recently shuttered WVVI tasting room in McMinnville, OR (November 2025) Date: November 18th 2025 Analyst: Drew Millegan & the Woodworth Contrarian Fund Originally posted on the Woodworth Contrarian Fund News page: https://www.woodworth.fund/news/willamette-valley-vineyards-wvvi-not-so-great-value Fair Value: Unclear. As an Oregon-based hedge fund, we often get the opportunity to more closely investigate local companies that are otherwise too small to register on most firms’ radars.Read more

FY3/27 expected to be a transitional year – AS ONE delivered full year operating profit growth ahead of revenue growth in FY3/26, demonstrating the operating leverage in its model. The FY3/27 financial guidance points to a year of growth investments, which should translate to profitability improvement in future years.Read more

IJM’s 4Q FY2026 headline numbers were clearly distorted, but the underlying read-through is more constructive than the reported loss suggests. While the Group recorded a 4Q FY2026 pre-tax loss of RM56.2 million, revenue still grew 4.2% YoY to RM1.87 billion.Read more

Writing this on last trading day (29th) of May 2026. OSEA is currently trading in the Rs.52-53 range...Read more

Here are data based on 3rd quarter: BVPS ~ EUR 171.5 Normalized ROE: 13–16% Payout: 50–60% CET1 above SREP Regarding publish strategy for the 2026 Strategy target: Recurring revenues: EUR 1.1bn → > EUR 2.0bn Profit: EUR 0.5bn → > EUR 1.0bn CIR: 46% → <45% ROE: >15% (including 1–2 p.p. uplift from strategic initiatives) P/B: 0.8x → >1.0x Payout ratio: 40% → 50–60% Capital and risk CET1: 16.4% → >13% Assumptions NIM remains >3.2% (this might be difficult to keep) CIR improves toward 43% (now is cca 45%) Strong growth in fee income ( they plan to proceed with acquisitions) ROE 16–17% ( now is around 15%) Payout 60% Outcome BVPS 2030: ~EUR 250 P/B: 1.15x Share price: ~EUR 285 Cumulative dividends: ~EUR 75 Total value in 2030: ~EUR 360 Scenario is bullish but there is a room to achieve this. A possible future greater presence on the Croatian market, which is burdened with certain problems from the political past of relations between Slovenia and Croatia, would probably catapult the share above €360 by 2030.Read more

A clinical-stage biotech, a new CEO, a Phase 2 readout in months, and a recent takeover deal that suggests CUE’s asset alone could be worth more than the whole company. Key Takeaways Cue Biopharma (NASDAQ: CUE) just transformed itself in 48 days: New CEO, raised $30 million, received a $7.5 million milestone from Boehringer Ingelheim, and in-licensed Ascendant-221 (CUE-221), a Phase 2 anti-IgE antibody aimed at Roche’s and Novartis AG’s (NVS) Xolair, which generated roughly $4.7 billion in 2025 sales.Read more

Investment Memorandum (Buffett-Style) – Shenzhou International Group ( 2313.HK ) Executive Summary Shenzhou International is a vertically integrated apparel manufacturer serving global brands, with a production footprint across China, Vietnam, and Cambodia. It combines scale, operational integration, and long-term customer relationships—traits that echo businesses Warren Buffett historically favors.Read more

Scicom looks like a routine outsourced support firm, but it’s quietly become a cash-rich, founder-led partner that runs customer service and digital systems for big names across the region. The surprising part is how steadily it turns day-to-day operations into cash while staying conservative, which could leave it overlooked and mispriced.Read more

A major overseas buyout turns Sudarshan into a truly global pigments player, and the latest results suggest the worst of the integration shock may be fading faster than many expected. The big question now is whether the recent pickup in European orders is a lasting recovery or just a seasonal bounce that could stall again.Read more